154 related articles for article (PubMed ID: 38404966)
1. Arginase-1 specific CD8+ T cells react toward malignant and regulatory myeloid cells.
Glöckner HJ; Martinenaite E; Landkildehus Lisle T; Grauslund J; Ahmad S; Met Ö; Thor Straten P; Hald Andersen M
Oncoimmunology; 2024; 13(1):2318053. PubMed ID: 38404966
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment.
Steggerda SM; Bennett MK; Chen J; Emberley E; Huang T; Janes JR; Li W; MacKinnon AL; Makkouk A; Marguier G; Murray PJ; Neou S; Pan A; Parlati F; Rodriguez MLM; Van de Velde LA; Wang T; Works M; Zhang J; Zhang W; Gross MI
J Immunother Cancer; 2017 Dec; 5(1):101. PubMed ID: 29254508
[TBL] [Abstract][Full Text] [Related]
3. Arginase 1-Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti-PD-1 Checkpoint Blockade.
Aaboe Jørgensen M; Ugel S; Linder Hübbe M; Carretta M; Perez-Penco M; Weis-Banke SE; Martinenaite E; Kopp K; Chapellier M; Adamo A; De Sanctis F; Frusteri C; Iezzi M; Zocca MB; Hargbøll Madsen D; Wakatsuki Pedersen A; Bronte V; Andersen MH
Cancer Immunol Res; 2021 Nov; 9(11):1316-1326. PubMed ID: 34518197
[TBL] [Abstract][Full Text] [Related]
4. Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells.
Weis-Banke SE; Lisle TL; Perez-Penco M; Schina A; Hübbe ML; Siersbæk M; Holmström MO; Jørgensen MA; Marie Svane I; Met Ö; Ødum N; Madsen DH; Donia M; Grøntved L; Andersen MH
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36316062
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer-derived GM-CSF regulates arginase 1 in myeloid cells to promote an immunosuppressive microenvironment.
Su X; Xu Y; Fox GC; Xiang J; Kwakwa KA; Davis JL; Belle JI; Lee WC; Wong WH; Fontana F; Hernandez-Aya LF; Kobayashi T; Tomasson HM; Su J; Bakewell SJ; Stewart SA; Egbulefu C; Karmakar P; Meyer MA; Veis DJ; DeNardo DG; Lanza GM; Achilefu S; Weilbaecher KN
J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34520398
[TBL] [Abstract][Full Text] [Related]
6. Arginase 1 is a key driver of immune suppression in pancreatic cancer.
Menjivar RE; Nwosu ZC; Du W; Donahue KL; Hong HS; Espinoza C; Brown K; Velez-Delgado A; Yan W; Lima F; Bischoff A; Kadiyala P; Salas-Escabillas D; Crawford HC; Bednar F; Carpenter E; Zhang Y; Halbrook CJ; Lyssiotis CA; Pasca di Magliano M
Elife; 2023 Feb; 12():. PubMed ID: 36727849
[TBL] [Abstract][Full Text] [Related]
7. Myeloid Cell Arg1 Inhibits Control of Arthritogenic Alphavirus Infection by Suppressing Antiviral T Cells.
Burrack KS; Tan JJ; McCarthy MK; Her Z; Berger JN; Ng LF; Morrison TE
PLoS Pathog; 2015 Oct; 11(10):e1005191. PubMed ID: 26436766
[TBL] [Abstract][Full Text] [Related]
8. Polymorphonuclear-MDSCs Facilitate Tumor Regrowth After Radiation by Suppressing CD8
Zhang Md J; Zhang Md L; Yang Md Y; Liu Md Q; Ma Md H; Huang Md A; Zhao Md Y; Xia Md Z; Liu Md T; Wu Md G
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1533-1546. PubMed ID: 33238192
[TBL] [Abstract][Full Text] [Related]
9. Quantitative Multiplexed Analysis of Indoleamine 2,3-Dioxygenase (IDO) and Arginase-1 (ARG1) Expression and Myeloid Cell Infiltration in Colorectal Cancer.
Elomaa H; Härkönen J; Väyrynen SA; Ahtiainen M; Ogino S; Nowak JA; Lau MC; Helminen O; Wirta EV; Seppälä TT; Böhm J; Mecklin JP; Kuopio T; Väyrynen JP
Mod Pathol; 2024 Apr; 37(4):100450. PubMed ID: 38369188
[TBL] [Abstract][Full Text] [Related]
10. An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial.
Grauslund JH; Holmström MO; Martinenaite E; Lisle TL; Glöckner HJ; El Fassi D; Klausen U; Mortensen REJ; Jørgensen N; Kjær L; Skov V; Svane IM; Hasselbalch HC; Andersen MH
Front Immunol; 2023; 14():1117466. PubMed ID: 36911725
[TBL] [Abstract][Full Text] [Related]
11. Neutralization of NET-associated human ARG1 enhances cancer immunotherapy.
Canè S; Barouni RM; Fabbi M; Cuozzo J; Fracasso G; Adamo A; Ugel S; Trovato R; De Sanctis F; Giacca M; Lawlor R; Scarpa A; Rusev B; Lionetto G; Paiella S; Salvia R; Bassi C; Mandruzzato S; Ferrini S; Bronte V
Sci Transl Med; 2023 Mar; 15(687):eabq6221. PubMed ID: 36921034
[TBL] [Abstract][Full Text] [Related]
12. Myeloid arginase-1 controls excessive inflammation and modulates T cell responses in Pseudomonas aeruginosa pneumonia.
Haydar D; Gonzalez R; Garvy BA; Garneau-Tsodikova S; Thamban Chandrika N; Bocklage TJ; Feola DJ
Immunobiology; 2021 Jan; 226(1):152034. PubMed ID: 33278710
[TBL] [Abstract][Full Text] [Related]
13. Ginseng-derived nanoparticles reprogram macrophages to regulate arginase-1 release for ameliorating T cell exhaustion in tumor microenvironment.
Lv Y; Li M; Weng L; Huang H; Mao Y; Yang DA; Wei Q; Zhao M; Wei Q; Rui K; Han X; Fan W; Cai X; Cao P; Cao M
J Exp Clin Cancer Res; 2023 Nov; 42(1):322. PubMed ID: 38012650
[TBL] [Abstract][Full Text] [Related]
14. Increased myeloid-derived suppressor cells in patients with myelodysplastic syndromes suppress CD8+ T lymphocyte function through the STAT3-ARG1 pathway.
Qi X; Jiang H; Liu P; Xie N; Fu R; Wang H; Liu C; Zhang T; Wang H; Shao Z
Leuk Lymphoma; 2021 Jan; 62(1):218-223. PubMed ID: 32985300
[TBL] [Abstract][Full Text] [Related]
15. Increased number of arginase 1-positive cells in the stroma of carcinomas compared to precursor lesions and nonneoplastic tissues.
Jang TJ; Kim SA; Kim MK
Pathol Res Pract; 2018 Aug; 214(8):1179-1184. PubMed ID: 29970307
[TBL] [Abstract][Full Text] [Related]
16. The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines.
Weis-Banke SE; Hübbe ML; Holmström MO; Jørgensen MA; Bendtsen SK; Martinenaite E; Carretta M; Svane IM; Ødum N; Pedersen AW; Met Ö; Madsen DH; Andersen MH
Oncoimmunology; 2020 Jun; 9(1):1771142. PubMed ID: 32923127
[TBL] [Abstract][Full Text] [Related]
17. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.
Liu CY; Wang YM; Wang CL; Feng PH; Ko HW; Liu YH; Wu YC; Chu Y; Chung FT; Kuo CH; Lee KY; Lin SM; Lin HC; Wang CH; Yu CT; Kuo HP
J Cancer Res Clin Oncol; 2010 Jan; 136(1):35-45. PubMed ID: 19572148
[TBL] [Abstract][Full Text] [Related]
18. A Novel Oral Arginase 1/2 Inhibitor Enhances the Antitumor Effect of PD-1 Inhibition in Murine Experimental Gliomas by Altering the Immunosuppressive Environment.
Pilanc P; Wojnicki K; Roura AJ; Cyranowski S; Ellert-Miklaszewska A; Ochocka N; Gielniewski B; Grzybowski MM; Błaszczyk R; Stańczak PS; Dobrzański P; Kaminska B
Front Oncol; 2021; 11():703465. PubMed ID: 34504786
[TBL] [Abstract][Full Text] [Related]
19. Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope.
Martinenaite E; Ahmad SM; Bendtsen SK; Jørgensen MA; Weis-Banke SE; Svane IM; Andersen MH
Cancer Immunol Immunother; 2019 Nov; 68(11):1901-1907. PubMed ID: 31690955
[TBL] [Abstract][Full Text] [Related]
20. Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors - A phase I trial.
Lorentzen CL; Martinenaite E; Kjeldsen JW; Holmstroem RB; Mørk SK; Pedersen AW; Ehrnrooth E; Andersen MH; Svane IM
Front Immunol; 2022; 13():1023023. PubMed ID: 36330525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
